Posts

The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach

4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.

“OA-BIO Eurostars grant represents a unique opportunity to bring together some of the most renowned European teams in the field of OA biomarkers […]”, said Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of the INSERM UMR-S938 research.

 

“OA-BIO […] will advance our understanding on OA biomarkers across the species that typically suffer from OA, like horses and dogs […]”, added Prof. Marianna Tryfonidou, Professor of Regenerative Orthopedics at Faculty of Veterinary Medicine of Utrecht University.

 

“[…] OA-BIO has a large potential to promote the understanding of the disease and to make a step towards urgently needed therapies”, completed Prof. Felix Eckstein, CEO/CMO of Chondrometrics.

 

“The OA-BIO consortium breakthrough lies in correlating OA imaging biomarkers with OA molecular ones, […] , as well as to follow how the innovative 4P004 treatment will efficiently interfere with the progression of the OA disease. […]”, concluded Prof. Mauro Alini, Vice-Director of ARI.

Read the full press release:
EN: 20210520_PR_4Mov_Eurostars_vEN
FR: 20210520_PR_4Mov_Eurostars_vFR

Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.

“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks. […]”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma.

 

“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004. […]”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France).

Read the full press release:
EN: 20210429_PR_4Mov_Closing_vEN
FR: 20210429_PR_4Mov_Financement_FR

Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis.

The Seal of Excellence is a high-quality label awarded by a panel of international independent experts. 4Moving Biotech project was scored as a high-quality proposal in a highly competitive evaluation process, it recognizes the high value of our breakthrough treatment at EU level.

4Moving Biotech au congrès de la SFR

Le Pr. Francis Berenbaum (chef du service de Rhumatologie de l’Hôpital Saint-Antoine et professeur de rhumatologie à Sorbonne Université, Paris) présentera nos résultats sur le projet 4P004 au 33ème congrès de la Société Française de Rhumatologie (SFR), du 13 au 16 décembre 2020, édition digitale.

Sa présentation, intitulée « Le liraglutide comme traitement intra-articulaire potentiel pour la régénération du cartilage dans l’arthrose : études in vitro et in vivo supportant un effet pro-chondrogénique » (#O.068) sera visible le dimanche 13 décembre en vidéo à la demande dans la session scientifique arthrose.

Pour plus d’informations : https://sfr2020.process.y-congress.com/ScientificProcess/schedule/index.html

 

4P-Pharma will give a talk during the DDIP 2020

4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET.

To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to contact Patrice or Roselina Lam, our Business Developer, via email.

For further information, please follow the link : https://worldbigroup.com/conference/ddip-virtual-series/

4P-Pharma est dans l’émission SMART FUTUR

Revital Rattenbach, Présidente de 4P-Pharma, a été interviewée dans l’émission SMART FUTUR diffusée le samedi 7 novembre 2020 sur BSMART.

Lors de cette émission, Revital a présenté 4P-Pharma ainsi que les dernières innovations qui animent l’équipe : 4P004, notre traitement pour l’arthrose et 4P021, notre solution contre la COVID-19.

Pour plus d’information : https://www.bsmart.fr/video/1121-smart-futur-emission-07-novembre-2020

Le Pr Francis Berenbaum reçoit le prix Fondation Guillaumat-Piel 2020 de la FRM

Toute l’équipe de 4P-Pharma est fière d’annoncer que le Pr Francis Berenbaum a remporté le prix Fondation Guillaumat-Piel 2020 de la Fondation pour la Recherche Médicale (FRM)  pour ses travaux sur les maladies ostéo-articulaires !

Nous collaborons avec Francis Berenbaum depuis plusieurs années sur le développement de 4P004, notre solution thérapeutique pour enrayer l’arthrose.

Francis Berenbaum est professeur de rhumatologie à la Faculté de médecine Sorbonne Université, chef du service de Rhumathologie de l’hôpital Saint-Antoine AP-HP et responsable de l’équipe « maladies métaboliques et pathologies liées au vieillissement » (UMR-S-938, Inserm).

Pour plus d’informations : https://www.frm.org/nos-publications/actualites/prix-frm-2020#b